Taiwan · Delayed Price · Currency is TWD Taiyen Biotech Statistics
Total Valuation
Taiyen Biotech has a market cap or net worth of TWD 6.33 billion. The enterprise value is 4.79 billion.
| Market Cap | 6.33B |
| Enterprise Value | 4.79B |
Important Dates
The next estimated earnings date is Tuesday, March 10, 2026.
| Earnings Date | Mar 10, 2026 |
| Ex-Dividend Date | Aug 20, 2025 |
Share Statistics
Taiyen Biotech has 200.00 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | 200.00M |
| Shares Outstanding | 200.00M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 12.32% |
| Float | 108.05M |
Valuation Ratios
The trailing PE ratio is 19.06.
| PE Ratio | 19.06 |
| Forward PE | n/a |
| PS Ratio | 1.93 |
| PB Ratio | 0.95 |
| P/TBV Ratio | 0.95 |
| P/FCF Ratio | 22.78 |
| P/OCF Ratio | 11.57 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.69, with an EV/FCF ratio of 17.24.
| EV / Earnings | 14.37 |
| EV / Sales | 1.46 |
| EV / EBITDA | 7.69 |
| EV / EBIT | 12.51 |
| EV / FCF | 17.24 |
Financial Position
The company has a current ratio of 2.63, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.63 |
| Quick Ratio | 2.12 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.21 |
| Debt / FCF | 0.48 |
| Interest Coverage | 66.97 |
Financial Efficiency
Return on equity (ROE) is 4.95% and return on invested capital (ROIC) is 3.53%.
| Return on Equity (ROE) | 4.95% |
| Return on Assets (ROA) | 2.91% |
| Return on Invested Capital (ROIC) | 3.53% |
| Return on Capital Employed (ROCE) | 5.34% |
| Revenue Per Employee | 7.27M |
| Profits Per Employee | 740,973 |
| Employee Count | 487 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 5.05 |
Taxes
In the past 12 months, Taiyen Biotech has paid 96.34 million in taxes.
| Income Tax | 96.34M |
| Effective Tax Rate | 22.78% |
Stock Price Statistics
The stock price has increased by +0.32% in the last 52 weeks. The beta is 0.18, so Taiyen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | +0.32% |
| 50-Day Moving Average | 31.64 |
| 200-Day Moving Average | 32.18 |
| Relative Strength Index (RSI) | 51.29 |
| Average Volume (20 Days) | 107,289 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Taiyen Biotech had revenue of TWD 3.27 billion and earned 333.44 million in profits. Earnings per share was 1.66.
| Revenue | 3.27B |
| Gross Profit | 1.33B |
| Operating Income | 382.89M |
| Pretax Income | 422.94M |
| Net Income | 333.44M |
| EBITDA | 613.12M |
| EBIT | 382.89M |
| Earnings Per Share (EPS) | 1.66 |
Balance Sheet
The company has 1.67 billion in cash and 132.62 million in debt, with a net cash position of 1.54 billion or 7.70 per share.
| Cash & Cash Equivalents | 1.67B |
| Total Debt | 132.62M |
| Net Cash | 1.54B |
| Net Cash Per Share | 7.70 |
| Equity (Book Value) | 6.65B |
| Book Value Per Share | 33.23 |
| Working Capital | 1.68B |
Cash Flow
In the last 12 months, operating cash flow was 547.10 million and capital expenditures -269.27 million, giving a free cash flow of 277.82 million.
| Operating Cash Flow | 547.10M |
| Capital Expenditures | -269.27M |
| Free Cash Flow | 277.82M |
| FCF Per Share | 1.39 |
Margins
Gross margin is 40.50%, with operating and profit margins of 11.70% and 10.19%.
| Gross Margin | 40.50% |
| Operating Margin | 11.70% |
| Pretax Margin | 12.92% |
| Profit Margin | 10.19% |
| EBITDA Margin | 18.73% |
| EBIT Margin | 11.70% |
| FCF Margin | 8.49% |
Dividends & Yields
This stock pays an annual dividend of 1.30, which amounts to a dividend yield of 4.12%.
| Dividend Per Share | 1.30 |
| Dividend Yield | 4.12% |
| Dividend Growth (YoY) | 8.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 77.98% |
| Buyback Yield | -0.08% |
| Shareholder Yield | 4.04% |
| Earnings Yield | 5.27% |
| FCF Yield | 4.39% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 16, 2013. It was a reverse split with a ratio of 0.719181284.
| Last Split Date | Dec 16, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.719181284 |
Scores
Taiyen Biotech has an Altman Z-Score of 3.68 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.68 |
| Piotroski F-Score | 6 |